IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

Inclusion Criteria: * 1.Male or female patients aged ≥18 years; * 2.Diagnosis of eosinophilic leukemia (EL) established according to the WHO 2022 diagnostic criteria; * 3.Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts. * 4.Meet any of the following criteria for refractory/relapsed eosinophilic leukemia: * a) Inadequate response to standard therapy: failure to achieve complete remission (CR) after standard treatments (e.g., imatinib, corticosteroids, interferon-α, chemotherapy, etc.); * b) Disease progression/relapse within 6 months after achieving remission; * 5.Serum total bilirubin ≤1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; * 6.Left ventricular ejection fraction (LVEF) \>50% as assessed by echocardiography; * 7.Peripheral oxygen saturation (SpO₂) ≥92% on room air (without supplemental oxygen); * 8.Estimated life expectancy \>3 months; * 9.Eastern Cooperative Oncology Group (ECOG) performance status 0-1; * 10.Women and men of childbearing potential must agree to use appropriate, effective contraception prior to study entry, throughout the study period, and for 6 months after cell infusion (the safety of this therapy for unborn children is unknown and may pose potential risks); * 11.Patients who are willing to participate in this study and who are able to understand and voluntarily sign the written informed consent form. Exclusion Criteria: * 1.History of epilepsy or other central nervous system (CNS) disorders; * 2.Presence of any of the following:Hepatitis B surface antigen (HBsAg)-positive; Any of HBeAg, HBeAb, or HBcAb positive and detectable hepatitis B virus (HBV) DNA in peripheral blood above the lower limit of detection; Hepatitis C virus (HCV) antibody-positive; Human immunodeficiency virus (HIV) antibody-positive; Positive serologic test for syphilis; * 3.History of QT interval prolongation or severe cardiac disease; * 4.Presence of uncontrolled active infection; * 5.Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the interpretation of the study results.